Neutropenia Biologic Drug Treatment Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The Business Research Company’s Neutropenia Biologic Drug Treatment Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK, April 7, 2022 /EINPresswire.com/ -- TBRC’s neutropenia biologic drug treatment market overview shows that companies are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells, and is used for treating severe neutrophil-mediated disease.

In September 2020, Gilead Sciences, a US-based biopharmaceutical company launched Immunomedics for $21 billion. Through this acquisition Gilead will get TrodelvyTM (acituzumab govitecan-hziy), which will alter Gilead’s portfolio by adding a first-in-class commercial drug with considerable revenue potential and best-in-class potential. Immunomedics is a US-based biotechnology company that offers neutropenia biologic drug treatment.

Read more on the Global Neutropenia Biologic Drug Treatment Market Report
https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

The global neutropenia biologic drug treatment market size is expected to grow from $10.22 billion in 2021 to $11.26 billion in 2022 at a compound annual growth rate (CAGR) of 10.2%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The neutropenia biologic drug market is expected to reach $14.78 billion in 2026 at a CAGR of 7.0%.

The rise in the number of cancer cases across the globe is likely to contribute to the neutropenia biologic drug treatment market growth. Due to a growing cancer incidence and an increase in the number of people opting for chemotherapy, there has been an increasing incidence in the number of people suffering from neutropenia. According to the neutropenia biologic drug treatment market forecast, the rise in cancer incidence rate globally is anticipated to boost the demand for the market over the forthcoming years.

Major players covered in the global neutropenia biologic drug treatment industry are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

TBRC’s global neutropenia biologic drug treatment market analysis report is segmented by drug type into filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, sargramostim, by treatment type into antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, others, by distribution channel into retail pharmacies, hospital pharmacies, online pharmacies.

Neutropenia Biologic Drug Treatment Global Market Report 2022 – By Drug Type (Filgrastim, Pegfilgrastim, Lenograstim, Lipegfilgrastim, Sargramostim), By Treatment Type (Antibiotic Drugs, Granulocyte-Colony-Stimulating Factor (G-CSF), Antifungal Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a neutropenia biologic drug treatment market overview, forecast neutropenia biologic drug treatment market size and growth for the whole market, neutropenia biologic drug treatment market segments, geographies, neutropenia biologic drug treatment market trends, neutropenia biologic drug treatment market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request for a Sample of the Global Neutropenia Biologic Drug Treatment Market Report
https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp

Not what you were looking for? Here is a list of similar reports by The Business Research Company:
Biologics Global Market Report 2022 – By Type (Monoclonal Antibodies (MAbs), Therapeutic Proteins, Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Parenteral), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/biologics-global-market-report

Filgrastim Biosimilars Global Market Report 2022 – By Application (Oncology, Chronic And Autoimmune Diseases, Blood Disorders, Growth Hormone Deficiency, Infectious Diseases), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Type Of Manufacturing (In-House Manufacturing, Contract Manufacturing Organization) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/filgrastim-biosimilar-global-market-report

Pegfilgrastim Biosimilars Global Market Report 2022 – By Application (Chemotherapy Treatment, Transplantation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail-Order Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
https://www.thebusinessresearchcompany.com/report/pegfilgrastim-biosimilar-global-market-report

About The Business Research Company?
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Check out our:
LinkedIn: https://bit.ly/3b7850r
Twitter: https://bit.ly/3b1rmjS
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: http://blog.tbrc.info/

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Market Research Products, Services, Solutions For Your Business - TBRC

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.